The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma

Annals of Surgery

Volumn 258, Issue 3, 2013, Pages 500-505

  Francis, Ashleigh M ^a   Sepesi, Boris ^a   Correa, Arlene M ^a   Blum, Mariela A ^a   Erasmus, Jeremy J ^a   Lee, Jeffrey H ^a   Maru, Dipen M ^a   Mehran, Reza J ^a   Rice, David C ^a   Roth, Jack A ^a   Vaporciyan, Ara A ^a   Walsh, Garrett L ^a   Welsh, James W ^a   Swisher, Stephen G ^a   Hofstetter, Wayne L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Esophageal adenocarcinoma; Histopathologic tumor viability; Neoadjuvant chemoradiation; Pathologic response; Survival outcomes

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONFERENCE PAPER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HISTOPATHOLOGIC TUMOR VIABILITY; HISTOPATHOLOGY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; PRIORITY JOURNAL;

ADENOCARCINOMA; CELL SURVIVAL; CHEMORADIOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884513946     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182a196f4     Document Type: Conference Paper

References (13)

1. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int J Cancer. 2008; 123: 1422-1428.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. vanHagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074-2084.
4. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681-692.
5. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals. Cancer. 2010; 116: 3763-3773.
6. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103: 1347-1355.
7. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005; 241: 810-817; discussion 817-820.
8. Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005; 104: 1349-1355.
9. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007; 31: 58-64.
10. Swisher SG, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004; 101: 1776-1785.
11. Mamede M, Abreu ELP, Oliva MR, et al. FDG-PET/CT tumor segmentationderived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007; 30: 377-388.
12. Pataer A, Kalhor N, Correa AM, et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012; 7: 825-832.
13. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009; 87: 392-398; discussion 398-399.